Literature DB >> 11818506

Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB.

Chiara Fiorentini1, Nicoletta Guerra, Marco Facchetti, Alessandra Finardi, Laura Tiberio, Luisa Schiaffonati, PierFranco Spano, Cristina Missale.   

Abstract

Two groups of prolactinoma cell lines were identified. One group (responder) expresses both D(2) dopamine receptors and an autocrine loop mediated by nerve growth factor (NGF) and one group (nonresponder) lacks both D(2) receptors and NGF production. D(2) receptor expression in these cell lines is dependent on NGF. Indeed, NGF inactivation in responder cells decreases D(2) receptor density, while NGF treatment induces D(2) receptor expression in nonresponders. Here we show that inactivation of p75(NGFR), but not of trkA, resulted in D(2) receptor loss in responder cells and prevented D(2) receptor expression induced by NGF in the nonresponder. Analysis of nuclear factor-kappaB (NF-kappaB) nuclear accumulation and binding to corresponding DNA consensus sequences indicated that in NGF-secreting responder cells, but not in nonresponders, NF-kappaB is constitutively activated. Moreover, NGF treatment of nonresponder cells induced both nuclear translocation and DNA binding activity of NF-kappaB complexes containing p50, p65/RelA, and cRel subunits, an effect prevented by anti-p75(NGFR) antibodies. Disruption of NF-kappaB nuclear translocation by SN50 remarkably impaired D(2) receptor expression in responder cells and prevented D(2) gene expression induced by NGF in nonresponders. These data indicate that in prolactinoma cells the effect of NGF on D(2) receptor expression is mediated by p75(NGFR) in a trkA-independent way and that NGF stimulation of p75(NGFR) activates NF-kappaB, which is required for D(2) gene expression. We thus suggest that NF-kappaB is a key transcriptional regulator of the D(2) gene and that this mechanism may not be confined to pituitary tumors, but could also extend to other dopaminergic systems.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818506     DOI: 10.1210/mend.16.2.0773

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  27 in total

1.  Neurotrophic actions initiated by proNGF in adult sensory neurons may require peri-somatic glia to drive local cleavage to NGF.

Authors:  Adrianna Kalous; Matthew R Nangle; Agustin Anastasia; Barbara L Hempstead; Janet R Keast
Journal:  J Neurochem       Date:  2012-06-12       Impact factor: 5.372

Review 2.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

Review 3.  Stem cells and targeted approaches to melanoma cure.

Authors:  George F Murphy; Brian J Wilson; Sasha D Girouard; Natasha Y Frank; Markus H Frank
Journal:  Mol Aspects Med       Date:  2013-10-19

4.  Dietary triglycerides as signaling molecules that influence reward and motivation.

Authors:  Chloé Berland; Céline Cansell; Thomas S Hnasko; Christophe Magnan; Serge Luquet
Journal:  Curr Opin Behav Sci       Date:  2016-03-18

Review 5.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 6.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

7.  A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence.

Authors:  Fan Wang; Arthur Simen; Albert Arias; Qun-Wei Lu; Huiping Zhang
Journal:  Hum Genet       Date:  2012-12-01       Impact factor: 4.132

8.  Nerve growth factor, D2 receptor isoforms, and pituitary tumors.

Authors:  Cristina Missale
Journal:  Endocrine       Date:  2012-12       Impact factor: 3.633

Review 9.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 10.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.